International Isotopes (INIS) AI Stock Analysis

International Isotopes

(Other OTC:INIS)

Select Model

Rating:43Neutral

Price Target:$0.04▼(-4.35% Downside)

Action:upgraded

Date:10/28/26

The overall score is very low, driven primarily by catastrophic financial performance including massive losses and cash burn. The recent corporate divestiture provides a potential lifeline by improving the balance sheet and strategic focus, but this is a secondary factor that does not offset the severe fundamental weakness. Technical trends are also bearish, and standard valuation metrics are inapplicable due to negative earnings.

Positive Factors

Strategic RefocusDivesting the unbuilt fuel-cycle project can sharpen management focus on radioisotope markets and provide funding for R&D, organic expansion, and acquisitions. If completed, the $9.5 million cash and equity consideration could improve strategic flexibility and support execution.

Negative Factors

Profitability DeteriorationThe recent combination of declining revenue, deeply negative operating and EBITDA margins, and an unusually large net loss indicates weak earnings quality and limited operating resilience. Sustained losses could consume resources and make future growth investment more difficult to fund internally.

International Isotopes (INIS) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $26.46M
Dividend Yield: ―
Average Volume (3M): 59.34K
Price to Earnings (P/E): 0.0
Beta (1Y): 0.92
Revenue Growth: -23.73%
EPS Growth: -2800.00%
Country: US
Employees: 45
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

International Isotopes Business Overview & Revenue Model

Company Description

Radnostix, Inc. (INIS) is a company that specializes in the global manufacturing and sale of crucial nuclear medicine calibration and reference standards, cobalt-60 products, and offers contract services for producing radiopharmaceuticals and radioch...

How the Company Makes Money

INIS makes money by selling products and services tied to radioisotopes and the nuclear-medicine supply chain. Key revenue streams include: (1) Nuclear pharmacy and radiopharmaceutical-related services: the company earns revenue by preparing and dist...

International Isotopes Financial Statement Overview

Summary

Financial performance is critically weak. The TTM period shows a net loss of $908B on $11.2M revenue, a -80,878% net margin, negative operating and free cash flow, and a high debt-to-equity ratio of 2.7. Revenue is declining, and the company is burning cash, indicating severe distress.

Income Statement

1Very Negative

Balance Sheet

4Very Negative

Cash Flow

5Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Dec 2024	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	11.23M	13.07M	13.90M	12.27M	11.18M	9.66M
Gross Profit	3.56M	3.21M	8.65M	7.38M	6.29M	5.74M
EBITDA	-2.15M	-76.03K	738.32K	-187.14K	1.29M	607.84K
Net Income	-908.00B	-908.00K	8,574	-869.02K	-310.70K	-2.38M
Balance Sheet
Total Assets	16.65M	17.84M	17.16M	16.91M	16.24M	16.33M
Cash, Cash Equivalents and Short-Term Investments	1.20M	1.70M	1.95M	2.69M	2.38M	474.85K
Total Debt	9.21M	4.84M	8.36M	8.34M	4.05M	4.46M
Total Liabilities	14.75M	14.14M	12.81M	12.87M	11.90M	13.60M
Stockholders Equity	1.89M	3.69M	4.35M	4.04M	4.34M	2.73M
Cash Flow
Free Cash Flow	-925.24K	86.01K	-82.43K	433.53K	-1.62M	-367.39K
Operating Cash Flow	-376.28K	620.16K	638.78K	582.59K	-1.50M	-161.91K
Investing Cash Flow	-548.96K	-534.15K	-685.22K	-149.06K	3.88M	-205.47K
Financing Cash Flow	319.05K	-275.86K	-145.23K	-80.50K	-472.00K	-78.70K

International Isotopes Technical Analysis

Technical Analysis SentimentNegative

Last Price0.05

Price Trends

50DMA0.05Negative

100DMA0.06Negative

200DMA0.07Negative

Market Momentum

MACD-0.00Negative

RSI50.61Neutral

STOCH52.78Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INIS, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 50.61 is Neutral, neither overbought nor oversold. The STOCH value of 52.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INIS.

International Isotopes Risk Analysis

International Isotopes disclosed 23 risk factors in its most recent earnings report. International Isotopes reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.If the FDA concludes that we have failed to comply with applicable regulations, it could take various actions including: issuing warning letters, imposing civil or criminal penalties, suspending regulatory approvals, requiring product recalls, seizing products, or enjoining future violations. Such enforcement actions could have a material adverse effect on our business, results of operations and financial condition.Q2, 2026

International Isotopes Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

INIS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AYTU	62Neutral	$20.98M	-1.41	-52.89%	―	-13.27%	27.11%
RMTI	60Neutral	$28.50M	-5.09	-14.03%	―	-21.12%	-109.07%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCYX	47Neutral	$37.51M	-2.05	-21.10%	―	489.78%	45.39%
INIS	43Neutral	$24.48M	0.00	-9999.00%	―	-23.73%	-2800.00%
PRPH	41Neutral	$139.52K	-0.00	-1358.66%	―	―	―
TLPH	38Underperform	$53.46M	-3.23	-87.28%	―	-96.30%	35.57%

* Healthcare Sector Average

Performance Comparison

INIS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
INIS	International Isotopes Inc.	0.05	-0.06	-58.18%
TLPH	Talphera, Inc.	1.03	-0.38	-26.95%
PRPH	Prophase Labs	0.01	-3.24	-99.69%
RMTI	Rockwell Medical	7.07	-3.73	-34.54%
SCYX	SCYNEXIS Inc	3.77	-1.34	-26.21%
AYTU	Aytu BioScience	1.93	-0.28	-12.67%

International Isotopes Corporate Events

Business Operations and StrategyM&A Transactions

Radnostix Divests Uranium Assets to Refocus on Isotopes

Positive

Oct 1, 2026

On September 28, 2026, Radnostix Inc. and its wholly owned subsidiary International Isotopes Fluorine Products agreed to sell all assets tied to a planned depleted uranium deconversion and fluorine extraction plant in Hobbs, New Mexico to Nano Nuclea...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026

International Isotopes AI Stock Analysis